In some studies, EGFR mutations presented as an improved prognostic factor for recurrence rate or overall survival even in operable NSCLC [13,14,15], while others showed that EGFR mutations are not a prognostic factor in early-stage NSCLC [11,16]. Here, EGFR is linked to non-small cell lung carcinoma.